Dermatology

Dermatology
Audio Summaries

The literature in dermatology doesn't slow down, and the papers you skip might be the ones that change your practice. OSLR turns the journals you'd read if you had the time into 3-minute audio summaries. Listen on your commute, between cases, whenever.

7 active journals687 audio summaries

Recent summaries

The latest articles summarized from dermatology journals.

Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.

Lancet (London, England)|Nov 19, 2026

Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndromes, mainly affecting younger women, and is likely more common than previously thought. This Review synthesizes current evidence on SCAD's epidemiology, mechanisms (including genetic susceptibility), diagnosis, management, and implications for reproductive and women's health. It also identifies research priorities, since evidence guiding pharmacological and interventional treatment remains scarce, even though most patients heal spontaneously and are best managed conservatively.

Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).

Lancet (London, England)|Nov 19, 2026

This study compares reproductive health indicators among women aged 16-54 in Britain using nationally representative Natsal surveys from 2010-2012 (Natsal-3) and 2022-2024 (Natsal-4), asking whether reproductive autonomy has improved and how it varies across social groups. Key findings include an increase in lifetime abortion (16.0% to 20.7%), a rise in women aged 16-44 reporting they definitely do not want children (7.7% to 16.6%), and a sharp drop in hormonal contraception use among women under 35. Persistent gaps remain: 18.5% of women at risk of unintended pregnancy reported no effective contraception, and women with lower education, greater deprivation, or Black African/Caribbean/Black British ethnicity faced higher risks of no effective contraception and abortion.

Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.

Lancet (London, England)|Nov 19, 2026

This cluster-randomised trial asked whether seasonal mass vaccination with the R21/Matrix-M malaria vaccine, given before peak transmission, could reduce malaria infection prevalence and be safe in The Gambia (low-to-moderate transmission) and Burkina Faso (intense seasonal transmission). Across 54 villages, three monthly doses reduced the odds of P. falciparum infection at peak transmission by 70% in The Gambia (aOR 0.30) and by 25% in Burkina Faso (aOR 0.75), with the vaccine judged safe and well tolerated. The authors conclude that seasonal mass vaccination could be an additional malaria control strategy in seasonal transmission settings, though its effect was considerably larger in The Gambia than in Burkina Faso.

Assessing Multiple Treatment Regimens for Tuberculosis.

The New England journal of medicine|Nov 19, 2026

This phase 2 randomized trial (PARADIGM4TB) asked whether new four-drug regimens containing ganfeborole and/or BTZ-043 could shorten or improve tuberculosis treatment compared with the standard 24-week HRZE regimen, using early sputum culture clearance (log10 time-to-positivity slope) as the primary measure. Two regimens, ganfeborole-bedaquiline-pretomanid-moxifloxacin (BPMG) and BTZ-043-bedaquiline-delamanid-moxifloxacin (BDMT), showed a posterior probability of superiority over HRZE of 0.83 and 0.99, respectively, with acceptable safety profiles to advance to further evaluation. The results were used to select regimens for further study rather than to establish definitive efficacy.

Acute Respiratory Distress Syndrome.

The New England journal of medicine|Nov 18, 2026

This review by Calfee and McAuley summarizes the current understanding of acute respiratory distress syndrome (ARDS), a common cause of acute hypoxemic respiratory failure. It addresses the key management challenges, including treating the underlying trigger, avoiding ventilator-induced lung injury and volume overload, and resolving controversies around supporting nonintubated patients, personalizing positive end-expiratory pressure, using innovative ventilation strategies, and giving glucocorticoids. The authors also highlight whether precision medicine approaches based on biologic, radiographic, or physiologic subphenotypes can improve outcomes.

Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.

Lancet (London, England)|Nov 17, 2026

This first-in-human phase 1 trial tested TriPRIL, an autologous CAR T-cell therapy that uses an engineered trimeric form of the natural ligand APRIL to simultaneously target BCMA and TACI, aiming to reduce antigen escape in relapsed or refractory multiple myeloma. In 15 infused patients (nine of whom had prior BCMA-directed CAR T therapy), the therapy showed a manageable safety profile, with no dose-limiting toxicities or treatment-related deaths, and cytokine release syndrome was limited to grade 1-2. The recommended phase 2 dose was set at 3.0 × 10^8 cells, supporting further investigation of this dual-targeted, natural ligand-based approach.

Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age.

The New England journal of medicine|Nov 16, 2026

This phase 3, double-blind, placebo-controlled trial asked whether once-weekly semaglutide could safely and effectively reduce body-mass index in children aged 6 to under 12 years with obesity, a group with few durable medical treatment options. Among 167 children randomized 2:1 to semaglutide or placebo alongside lifestyle counseling, semaglutide produced a mean BMI reduction of 13.5% versus a 2.7% increase with placebo at week 68 (between-group difference -16.2 percentage points). Gastrointestinal adverse events were more common with semaglutide, but led to discontinuation in only one participant in that group.

Lynch syndrome.

Lancet (London, England)|Nov 12, 2026

Lynch syndrome, caused by germline mismatch repair gene variants, is the most common inherited cancer predisposition syndrome, yet most carriers remain undiagnosed. This review asks how scientific advances in biology, diagnosis, prevention, and treatment can be translated into equitable, effective care across the full continuum, from case identification through cascade testing. The authors highlight that universal tumour testing and immune checkpoint inhibitors have transformed the field, but that inconsistent implementation and access gaps continue to limit benefit.

Empirical tuberculosis treatment in infants living with HIV hospitalised with severe pneumonia in Africa (EMPIRICAL): a multicentre, randomised, open-label, 2 × 2 factorial, controlled superiority trial.

Lancet (London, England)|Nov 12, 2026

The EMPIRICAL trial asked whether starting empirical tuberculosis treatment for HIV-exposed infants hospitalised with severe pneumonia in Africa reduces mortality compared with a microbiologically and clinically guided approach. In this factorial randomised trial of 558 infants, empirical TB treatment did not significantly reduce all-cause mortality at 12 months (48% vs 43% died; adjusted HR 1.12, 95% CI 0.87-1.43), though nearly half of the comparison group eventually started TB treatment, which may have diluted the contrast. The findings indicate no evidence that empirical TB treatment is superior to the current guided strategy, while valganciclovir showed no interaction with it.

Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.

Lancet (London, England)|Nov 11, 2026

The COURAGE trial asked whether blocking myostatin (GDF8) with trevogrumab, alone or combined with activin A blockade via garetosmab, could preserve lean mass during semaglutide-induced weight loss in adults with obesity. Trevogrumab significantly preserved lean mass relative to semaglutide plus placebo (about +1.5% to +3.1% treatment differences, depending on dose and part), and trevogrumab was generally well tolerated, whereas the trevogrumab 400 mg plus garetosmab combination produced more fat loss and weight loss but had a high rate of serious adverse events, treatment discontinuations, and two deaths (not causally linked to treatment), with more frequent muscle spasms.

Start listening to dermatology research

14-day free trial. Pick your journals and go.